Samphire Neuroscience, a medtech startup, has announced a successful $2.3 million pre-seed funding round for its pioneering neurotechnology wearable, Nettle. Designed to manage premenstrual syndrome (PMS) and menstrual pain, Nettle represents a significant step forward in at-home neurostimulation treatment. With over 90% of women affected by menstrual pain and PMS at some point, the demand for such solutions is evident.
The funding round, which drew contributions from a number of venture firms experienced in medical devices and women’s health, will aid in bringing this innovative solution to a market that has long sought effective and side-effect-free options for menstrual symptom management. Participants in the round include SOSV, FIRSTPICK, Afterwork, Seaside, Ayuh, and CVX Ventures. The round also saw participation from prominent angel investors such as Dr Pamela Walker, founder of Thena Capital and Rowena Ironside, founder of Women on Boards UK.
Emilė Radytė, CEO and Co-Founder of Samphire Neuroscience, said: “Women’s health has been notoriously under-researched and underfunded for decades. As a result, women have been expected to compromise when it comes to taking care of their minds and bodies. What we’re doing is approaching things differently – with the brain as the nexus of health. A number of scientific studies have highlighted the potential of brain-based therapies. Mental and physical well-being are essential components of a complex system governed by the brain, and unlocking that system’s capabilities will lead to breakthroughs beyond our current understanding, and Samphire is going to help forge that path.”
Duncan Turner, General Partner at SOSV, added: “I have spent my career investing in mental health solutions, and was struck by how unique Samphire’s approach is. It not only pays attention to – and gives a solution for – challenges that are so common yet overlooked, but also aims to support women across their lives, so they could thrive.”
Nettle utilizes neurostimulation technology to address both the mental and physical aspects of menstrual symptoms. This approach not only aligns with the rising demand for natural health solutions but also positions Samphire Neuroscience at the forefront of women’s healthcare innovation. The product comes at a crucial time, as current treatments for chronic menstrual health conditions often involve invasive procedures or long-term medication with potential adverse effects. Nettle offers a non-invasive alternative that taps into the brain’s neuroplasticity, potentially providing relief without the risks associated with long-term medication use or surgery. As the company looks to the future, the implications of this neurotechnology could extend beyond menstrual health, potentially influencing broader aspects of women’s well-being and healthcare.
